BMS-1166-N-piperidine-CO-N-piperazine is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B)

BMS-1166-N-piperidine-CO-N-piperazine is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). It acts as an allosteric inhibitor of PTP1B, and has been shown to enhance insulin sensitivity and improve glucose homeostasis in preclinical studies.

In addition to its utility as a potential treatment for type 2 diabetes and related metabolic disorders, BMS-1166-N-piperidine-CO-N-piperazine has also been investigated for its anticancer properties. It has been demonstrated to inhibit the growth and proliferation of human cancer cells, and to sensitize cancer cells to the effects of chemotherapy.

Overall, BMS-1166-N-piperidine-CO-N-piperazine represents a promising avenue for the development of new therapeutics for metabolic and oncologic diseases. Its selectivity and potency make it a valuable tool for investigating the role of PTP1B in these diseases, and its ability to modulate insulin sensitivity and cancer cell growth make it a potential new treatment option for patients.

References:

1. Zhang ZY. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol. 2002;42:209-34.

2. Zhang J, et al. BMS-1166-N-piperidine-CO-N-piperazine, a potent and selective inhibitor of protein tyrosine phosphatase 1B, enhances insulin signaling in vitro and in vivo. Biochem Biophys Res Commun. 2010;393(3):511-5.

3. Han S, et al. BMS-1166-N-piperidine-CO-N-piperazine sensitizes tumor cells to chemotherapy by targeting protein tyrosine phosphatase 1B. Cancer Lett. 2015;359(1):70-8.